Journal article
Metabolic osteoarthritis – relation of diabetes and cardiovascular disease with knee osteoarthritis
Osteoarthritis and cartilage, Vol.29(2), pp.230-234
02/2021
DOI: 10.1016/j.joca.2020.09.010
PMCID: PMC8020447
PMID: 33253888
Abstract
There is an interest in identifying a metabolic OA phenotype. We therefore assessed the relation of diabetes and cardiovascular disease to prevalent and incident radiographic (ROA) and symptomatic knee osteoarthritis (SxOA).
In two large cohort studies of individuals with or at risk for knee OA, the Multicenter Osteoarthritis Study (MOST) and Osteoarthritis Initiative (OAI), participants self-reported diabetes and cardiovascular disease (CVD) at baseline. We assessed the relation of baseline diabetes and CVD (exposures) to ROA and SxOA cross-sectionally and after 60 (MOST) or 48 (OAI) months of follow-up using logistic regression with GEE to account for 2 knees within an individual, adjusting for potential confounders.
In MOST, 6,020 knees of 3,021 participants (60.1% female, mean ± SD age 62.5 ± 8.1, mean BMI 30.7 ± 6.0, 83.3% Caucasian) were included in the analyses. In OAI, 8,645 knees of 4,339 participants (58.2% female, mean ± SD age 61.1 ± 9.2, mean BMI 28.6 ± 4.8, 80.3% Caucasian) were included. We found no significant associations between prevalent diabetes or CVD and prevalent or incident ROA or SxOA. Effect estimates for prevalent ROA and SxOA ranged from 0.80 (95% CI 0.63–1.03) to 1.17 (0.91–1.51). Effect estimates for incident ROA ranged from 0.80 (0.58–1.11) to 0.88 (0.60–1.29) in MOST and from 0.75 (0.50–1.14) to 1.19 (0.81–1.74) in OAI, and for incident SxOA from 0.93 (0.65–1.31) to 1.22 (0.89–1.67) in MOST and from 0.82 (0.59–1.16) to 1.19 (0.85–1.66) in OAI).
Diabetes and CVD were not associated with prevalent or incident knee OA.
Details
- Title: Subtitle
- Metabolic osteoarthritis – relation of diabetes and cardiovascular disease with knee osteoarthritis
- Creators
- L Kuusalo - Centre for Rheumatology and Clinical Immunology, Division of Medicine, University of Turku and Turku University Hospital, Turku, FinlandD.T Felson - Section of Rheumatology, Department of Medicine, Boston University School of Medicine, Boston, MA, USAN Wang - Boston University School of Public Health, Boston, MA, USAC.E Lewis - Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, USAJ Torner - University of Iowa, Iowa City, IA, USAM.C Nevitt - Epidemiology and Biostatistics, UCSF, San Francisco, CA, USAT Neogi - Section of Rheumatology, Department of Medicine, Boston University School of Medicine, Boston, MA, USAMulticenter Osteoarthritis Study Group
- Resource Type
- Journal article
- Publication Details
- Osteoarthritis and cartilage, Vol.29(2), pp.230-234
- DOI
- 10.1016/j.joca.2020.09.010
- PMID
- 33253888
- PMCID
- PMC8020447
- NLM abbreviation
- Osteoarthritis Cartilage
- ISSN
- 1063-4584
- eISSN
- 1522-9653
- Publisher
- Elsevier Ltd
- Grant note
- DOI: 10.13039/100004330, name: GlaxoSmithKline; DOI: 10.13039/100000002, name: National Institutes of Health; DOI: 10.13039/100004334, name: Merck; DOI: 10.13039/100000009, name: Foundation for the National Institutes of Health; DOI: 10.13039/100008272, name: Novartis Pharmaceuticals Corporation; DOI: 10.13039/100000016, name: U.S. Department of Health and Human Services; DOI: 10.13039/100000049, name: National Institute on Aging, award: K24 AR070892, N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260, N01-AR-2-2261, N01-AR-2-2262, P30 AR072571, U01-AG18947, U01-AG19069, U01–AG18820, U01–AG18832; DOI: 10.13039/100004319, name: Pfizer
- Language
- English
- Date published
- 02/2021
- Academic Unit
- Epidemiology; Surgery; Injury Prevention Research Center; Neurosurgery
- Record Identifier
- 9984214810602771
Metrics
10 Record Views